Danaher (NYSE:DHR) posted its earnings results on Thursday. The conglomerate reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.05 by $0.41, MarketWatch Earnings reports. The firm had revenue of $7.22 billion during the quarter, compared to analysts’ expectations of $6.71 billion. Danaher had a return on equity of 16.34% and a net margin of 19.17%. The company’s revenue was up 36.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.44 earnings per share.
DHR traded up $9.65 during trading hours on Thursday, reaching $289.45. The company’s stock had a trading volume of 138,309 shares, compared to its average volume of 2,174,544. The company’s 50-day simple moving average is $261.17. Danaher has a 52 week low of $190.34 and a 52 week high of $287.00. The firm has a market cap of $206.46 billion, a price-to-earnings ratio of 45.27, a PEG ratio of 1.77 and a beta of 0.69. The company has a current ratio of 2.05, a quick ratio of 1.70 and a debt-to-equity ratio of 0.55.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 30th. Shareholders of record on Friday, June 25th will be paid a $0.21 dividend. The ex-dividend date is Thursday, June 24th. This represents a $0.84 annualized dividend and a yield of 0.29%. Danaher’s dividend payout ratio is 13.31%.
A hedge fund recently raised its stake in Danaher stock. Camden National Bank lifted its position in shares of Danaher Co. (NYSE:DHR) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,817 shares of the conglomerate’s stock after acquiring an additional 65 shares during the period. Camden National Bank’s holdings in Danaher were worth $1,292,000 as of its most recent filing with the Securities and Exchange Commission. 77.50% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently issued reports on DHR. Jefferies Financial Group boosted their price objective on Danaher from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Friday, April 23rd. Robert W. Baird increased their price objective on shares of Danaher from $249.00 to $270.00 and gave the stock an “outperform” rating in a research report on Friday, April 23rd. Citigroup raised their price objective on shares of Danaher from $275.00 to $315.00 in a report on Friday, April 23rd. William Blair reissued an “outperform” rating on shares of Danaher in a research note on Monday, April 26th. Finally, Credit Suisse Group upped their price objective on Danaher from $282.00 to $288.00 and gave the stock an “outperform” rating in a research report on Friday, June 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company. Danaher presently has an average rating of “Buy” and a consensus price target of $280.27.
Danaher Company Profile
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines.
Featured Story: What are economic reports?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.